Form 4: ACELYRIN Director's Equity Holdings Convert to Alumis Shares Following Merger Completion

A recent SEC Form 4 filing reveals that ACELYRIN, Inc. Director Lynn A. Tetrault's equity and stock options in ACELYRIN have been converted into shares and options of Alumis, Inc. following the merger of the two companies.

Summary

• ACELYRIN, Inc. Director Lynn A. Tetrault's beneficial ownership of ACELYRIN securities has changed to zero following the company's merger with Alumis, Inc.
• The merger, effective May 21, 2025, involved ACELYRIN becoming a wholly-owned subsidiary of Alumis, Inc.
• Each outstanding share of ACELYRIN common stock was converted into the right to receive 0.4814 shares of Alumis, Inc. common stock.
• ACELYRIN stock options with an exercise price of $18.00 or less were assumed by Alumis, Inc. and converted based on the 0.4814 exchange ratio.
• Specifically, Lynn A. Tetrault's 43,680 ACELYRIN stock options with an exercise price of $4.46 were converted into Alumis options (implicitly 21,030 Alumis shares at an exercise price of $9.27).
• Additionally, 89,955 ACELYRIN stock options with an exercise price of $7.29 were converted into Alumis options (implicitly 43,319 Alumis shares at an exercise price of $15.15).

Sentiment

Score: 7

Explanation: The document reports a standard, expected outcome of a corporate merger, indicating the successful completion of a strategic transaction. While not inherently 'positive' in terms of new news, it reflects a planned corporate action being executed as anticipated, which is generally a neutral to slightly positive signal for operational stability post-merger.

Positives

• The successful completion of the merger indicates a strategic consolidation, potentially offering new growth avenues under the Alumis, Inc. umbrella.
• The conversion of options ensures continuity of equity incentives for the director within the new corporate structure.

Negatives

• The filing itself does not present explicit negative financial outcomes for the reporting person, as it details a standard conversion process post-merger.

Future Outlook

The document primarily reports a completed transaction (merger and subsequent equity conversion) and does not provide forward-looking statements or guidance regarding the future performance of Alumis, Inc. or the former ACELYRIN operations.

Industry Context

This filing reflects a common outcome of corporate mergers in the biotechnology or pharmaceutical sector, where the acquiring company integrates the target company's equity structure. Such transactions aim to consolidate assets, intellectual property, and talent, potentially leading to synergies and expanded market presence for the combined entity, Alumis, Inc.

Stakeholder Impact

• Shareholders of ACELYRIN, Inc. have had their shares converted into Alumis, Inc. common stock, impacting their future investment in the combined entity.
• Employees of ACELYRIN, Inc. holding stock options would also see their options converted to Alumis, Inc. options, aligning their incentives with the new parent company.

Next Steps

• Continued integration of ACELYRIN, Inc. as a wholly-owned subsidiary of Alumis, Inc.
• Ongoing vesting of converted stock options for Lynn A. Tetrault based on continued service.

Key Dates

Keywords

ACELYRIN, SLRN, Alumis, Merger, Form 4, SEC Filing, Stock Options, Beneficial Ownership, Director, Equity Conversion, Corporate Action